波士顿II型人工角膜恢复严重瘢痕性眼表疾病患者视力
回顾性队列研究纳入2009年6月至2021年3月连续接受波士顿II型人工角膜(BK2)植入的56眼(53例),平均随访45.8个月。视力从术前logMAR 2.2±0.5改善至末次随访1.5±1.2,50眼术后曾达≥20/200;随访超5年者50.0%末次随访仍保持≥20/200。结论认为器械设计与术后护理进步使BK2成为严重瘢痕性眼表疾病角膜盲的可行选择。
要点
- 56眼(53例)BK2植入后视力从术前logMAR 2.2±0.5改善至末次随访1.5±1.2。
- 56眼中50眼术后某时点视力≥20/200;随访超5年者50.0%末次随访仍≥20/200。
- 最常见并发症为新生或加重青光眼41.1%、脉络膜渗出30.3%、视网膜脱离25.0%、终末期青光眼25.0%。
核心结论
- 器械设计与术后护理的进步使BK2植入成为严重瘢痕性眼表疾病所致角膜盲的可行选择。
研究设计与样本
- 回顾性队列研究,纳入2009年6月至2021年3月连续接受BK2植入的56眼(53例),平均随访45.8个月(范围0.2-134.7个月)。
主要发现
- 最常见适应证为Stevens-Johnson综合征/中毒性表皮坏死松解症(49.1%),其次为黏膜类天疱疮(39.6%)和其他眼表疾病(11.3%)。
- 视力从术前logMAR 2.2±0.5改善至末次随访1.5±1.2。
- 56眼中50眼术后某时点视力≥20/200;随访超过5年的眼中50.0%末次随访视力≥20/200。
- 整个术后病程(平均约4年)最常见并发症为新生或加重青光眼(41.1%)、脉络膜渗出(30.3%)、视网膜脱离(25.0%)和终末期青光眼(25.0%)。
- 单因素分析显示,发生不可逆视力丧失至≥20/200以下的患者较保持≥20/200者更可能曾植入旧设计BK2、更少接受术前全身免疫抑制治疗、更少同时行青光眼引流管植入(P值均<.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess clinical outcomes of patients with severe, cicatricial ocular surface disease (OSD) implanted with the currently marketed design of the Boston keratoprosthesis type II (BK2). DESIGN: Retrospective cohort study. METHODS: Records of consecutive patients undergoing BK2 implantation from June 2009 to March 2021 were assessed for postoperative visual acuity, postoperative complications, device replacement, and additional surgeries. RESULTS: Fifty-six eyes of 53 patients with a mean follow-up of 45.8 months (range, 0.2-134.7 months) were included. Stevens-Johnson syndrome/toxic epidermal necrolysis was the most common indication (49.1%), followed by mucous membrane pemphigoid (39.6%) and other OSD (11.3%). Visual acuity improved from logMAR 2.2 ± 0.5 preoperatively to 1.5 ± 1.2 at final follow-up. Of 56 eyes, 50 saw ≥20/200 at some point postoperatively. Of the eyes with a follow-up of more than 5 years, 50.0% retained a visual acuity of ≥20/200 at their final follow-up. The most common complications over the entire postoperative course (mean ∼4 years) were de novo or worsening glaucoma (41.1%), choroidal effusions (30.3%), retinal detachment (25.0%), and end-stage glaucoma (25.0%). In a univariate analysis, patients who experienced irreversible loss of ≥20/200 visual acuity were more likely to have been previously implanted with an older design of BK2, less likely to be on preoperative systemic immunosuppressive therapy, and less likely to have undergone concurrent glaucoma tube implantation, compared to patients who retained ≥20/200 acuity (P < .04 for all). CONCLUSIONS: Advances in device design and postoperative care have made implantation of BK2 a viable option for corneal blindness in the setting of severe cicatricial OSD.
引用
- Saini C, Chen TC, Young LH, et al. Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II. Am J Ophthalmol. 2022. PMID: 35850253. doi:10.1016/j.ajo.2022.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。